Furthest along
3 in Phase 3
3 in Phase 2
Drugs
6
in active trials · 8 in all
Trials
10 active
16 since 2021
Drugs6
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 2/3 | 31 Dec 2026Phase 2/3 trial completes | |||
| Next date | 31 Dec 2026 · Phase 2/3 trial completes | ||||
| Also tested for | Idiopathic Pulmonary Fibrosis | ||||
| Open drug page | |||||
ROS1 inhibitor |
Phase 3 | 31 Oct 2027Phase 3 trial completes | |||
| Next date | 31 Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | Protein Kinase Inhibitors, Other Protocol Specified Criteria and 4 more | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Nov 2028Phase 3 trial completes | |||
| Next date | 30 Nov 2028 · Phase 3 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Breast Cancer | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Aug 2027Phase 2 trial completes | |||
| Next date | 30 Aug 2027 · Phase 2 trial completes | ||||
| Also tested for | Atopic Dermatitis (AD) | ||||
| Open drug page | |||||
— |
Phase 2 | — | |||
| Also tested for | Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC) and 2 more | ||||
| Open drug page | |||||
— |
Phase 2 | — | |||
| Also tested for | Moderate-to-severe Atopic Dermatitis, Neuromyelitis Optica Spectrum Disorders | ||||
| Open drug page | |||||
About
- No active trial
- DC371739, Singletine
- SEC filings
- None: it does not file with the US SEC
- Registry names
- 2 names in ClinicalTrials.gov Guangzhou JOYO Pharma Co., Ltd
Chengdu JOYO pharma Co., Ltd. - Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021